Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer

Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancerPrognostic impact of genetic variants of <i>CYP19A1</i> and <i>UGT2B17</i> in a randomized trial for endocrine-responsive postmenopausal breast cancer, Published online: 10 April 2019; doi:10.1038/s41397-019-0087-zPrognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer

Source: The Pharmacogenomics Journal - April 9, 2019 Category: Drugs & Pharmacology Authors: Harriet Johansson Valentina Aristarco Sara Gandini Jennifer Gjerde Debora Macis Aliana Guerrieri-Gonzaga Davide Serrano Matteo Lazzeroni Agnita Rajasekaran Clark V Williard Gunnar Mellgren Andrea DeCensi Bernardo Bonanni Source Type: research